$21.9 Billion is the total value of VIKING GLOBAL INVESTORS LP's 82 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | $359,132,000 | -17.6% | 88,238,700 | 0.0% | 1.64% | -6.8% | ||
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $242,649,000 | -41.7% | 29,993,708 | 0.0% | 1.11% | -34.0% | |
| BBIO | BRIDGEBIO PHARMA INC | $241,719,000 | -10.5% | 26,620,991 | 0.0% | 1.11% | +1.3% | |
| AMYLYX PHARMACEUTICALS INC | $138,105,000 | +49.9% | 7,170,536 | 0.0% | 0.63% | +69.4% | ||
| GUARDANT HEALTH INCnote 11/1 | $74,700,000 | -22.9% | 120,000,000 | 0.0% | 0.34% | -12.8% | ||
| INBX | INHIBRX INC | $60,222,000 | -49.1% | 5,305,866 | 0.0% | 0.28% | -42.5% | |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | $56,949,000 | -39.1% | 2,026,656 | 0.0% | 0.26% | -31.2% | |
| RALLYBIO CORP | $31,671,000 | +8.2% | 4,194,777 | 0.0% | 0.14% | +22.9% | ||
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $27,487,000 | -53.8% | 3,937,914 | 0.0% | 0.13% | -47.7% | |
| KNTE | KINNATE BIOPHARMA INC | $22,956,000 | +12.0% | 1,820,462 | 0.0% | 0.10% | +26.5% | |
| EWTX | EDGEWISE THERAPEUTICS INC | $21,709,000 | -17.9% | 2,727,249 | 0.0% | 0.10% | -7.5% | |
| NUVALENT INC | $15,054,000 | -2.4% | 1,110,170 | 0.0% | 0.07% | +11.3% | ||
| TALS | TALARIS THERAPEUTICS INC | $14,836,000 | -54.2% | 3,289,617 | 0.0% | 0.07% | -48.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VISA INC | 36 | Q3 2023 | 7.0% |
| AMAZON COM INC | 34 | Q3 2023 | 10.6% |
| META PLATFORMS INC | 34 | Q3 2023 | 10.4% |
| MICROSOFT CORP | 30 | Q3 2023 | 9.1% |
| THERMO FISHER SCIENTIFIC INC | 29 | Q3 2023 | 5.4% |
| NETFLIX INC | 26 | Q2 2023 | 6.0% |
| MASTERCARD INCORPORATED | 25 | Q3 2023 | 3.9% |
| ELEVANCE HEALTH INC | 24 | Q2 2023 | 10.2% |
| ALPHABET INC | 22 | Q2 2021 | 9.3% |
| UNITEDHEALTH GROUP INC | 22 | Q3 2023 | 5.3% |
View VIKING GLOBAL INVESTORS LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Celldex Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Coupa Software IncSold out | February 14, 2023 | 0 | 0.0% |
| FIGS, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Guardant Health, Inc. | February 14, 2023 | 4,107,644 | 4.0% |
| Orion Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| PROCEPT BioRobotics CorpSold out | February 14, 2023 | 0 | 0.0% |
| Frazier Lifesciences Acquisition CorpSold out | November 25, 2022 | 0 | 0.0% |
| Cazoo Group Ltd | November 10, 2022 | 60,000,000 | 7.3% |
| AbCellera Biologics Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View VIKING GLOBAL INVESTORS LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-20 |
| SC 13G/A | 2024-03-20 |
| 4 | 2024-03-07 |
| 4 | 2024-03-07 |
| 4 | 2024-03-01 |
| 4 | 2024-03-01 |
| SC 13G/A | 2024-03-01 |
| 4 | 2024-02-28 |
| 4 | 2024-02-28 |
| SC 13G/A | 2024-02-28 |
View VIKING GLOBAL INVESTORS LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.